Using ELISPOT to Expose False Positive Skin Test Conversion in Tuberculosis Contacts

Philip C. Hill*, David J. Jeffries, Roger H. Brookes, Annette Fox, Dolly Jackson-Sillah, Moses D. Lugos, Simon A. Donkor, Bouke C. de Jong, Tumani Corrah, Richard A. Adegbola, Keith P. McAdam

Bacterial Diseases Programme, Medical Research Council Unit, Banjul, The Gambia

Background. Repeat tuberculin skin tests may be false positive due to boosting of waned immunity to past mycobacterial exposure. We evaluated whether an ELISPOT test could identify tuberculosis (TB) contacts with boosting of immunity to non-tuberculous mycobacterial exposure. Methodology/Principal Findings. We conducted tuberculin and ELISPOT tests in 1665 TB contacts: 799 were tuberculin test negative and were offered a repeat test after three months. Those with tuberculin test conversion had an ELISPOT, chest X-ray and sputum analysis if appropriate. We compared converters with non-converters, assessed the probability of each of four combinations of ELISPOT results over the two time points and estimated boosting with adjustment for ELISPOT sensitivity and specificity. 704 (72%) contacts had a repeat tuberculin test; 176 (25%) had test conversion, which increased with exposure to a case (p = 0.002), increasing age (p = 0.0006) and BCG scar (p = 0.06). 114 tuberculin test converters had ELISPOT results: 16(14%) were recruitment positive/follow-up positive, 9 (8%) positive/negative, 34 (30%) negative/positive, and 55 (48%) were negative/negative. There was a significant non-linear effect of age for ELISPOT results in skin test converters (p = 0.038). Estimates of boosting ranged from 32%–41% of skin test converters with increasing age. Three converters were diagnosed with TB, two had ELISPOT results: both were positive, including one at recruitment. Conclusions/Significance. We estimate that approximately one third of tuberculin skin test conversion in Gambian TB case contacts is due to boosting of immunity to non-tuberculous mycobacterial exposure. Further longitudinal studies are required to confirm whether ELISPOT can reliably identify case contacts with tuberculin test conversion that would benefit most from prophylactic treatment.

INTRODUCTION

The period of highest risk for developing tuberculosis (TB) is in the first year after exposure to Mycobacterium tuberculosis.[1] Individuals most likely to be in this group are those who have a negative test for M. tuberculosis infection, exposure to a TB case and subsequent test conversion. However, conversion of the traditional tuberculin skin test can be confounded by the ‘booster’ phenomenon, whereby an initial tuberculin injection causes recall of waned cell-mediated immunity to previous, largely non-tuberculous, mycobacterial exposure. Tuberculin probably does not cause a truly ‘mycobacterially naive’ person to become positive on a subsequent test.[2]

Recently, the British National Institute for Health and Clinical Excellence (NICE) published recommendations suggesting that the traditional tuberculin test and an interferon-gamma test be used in a two-step manner – the tuberculin test as a screening tool and an interferon-gamma test as confirmation.[3] Such a strategy has not been assessed in practice. It is our view that such a two-step approach may be most appropriate when trying to distinguish true tuberculin skin test conversion from that due to the booster phenomenon, at least in relation to previous non-tuberculous exposure. One would expect such a phenomenon to occur most frequently where there is a high rate of BCG vaccination at birth and intense exposure to environmental mycobacteria, as these are particularly associated with early skin test reversion [4,5]. The Gambia is such a setting.

Cell based interferon-gamma assays that incorporate stimulatory antigens that are not found in BCG or many environmental mycobacteria, have been shown to have promise in the diagnosis of M. tuberculosis infection after recent exposure.[6,7,8] Here we assess whether ELISPOT has utility in distinguishing tuberculin skin test converters with true M. tuberculosis infection from those with boosting of immunity to prior, non-tuberculous, mycobacterial exposure.

METHODS

Participants

Consecutive recruitment of sputum smear and culture positive TB cases and their household contacts in The Gambia, plus the selection process for ELISPOT testing, have been described previously.[7] Household contacts of TB cases were eligible for inclusion in this study if they were at least 6 months old and had a recruitment ELISPOT result but were not diagnosed with TB disease. The study was approved by the combined Gambia Government/MRC ethics committee.

Contacts were interviewed, examined, and a blood sample taken for ELISPOT and HIV test. Immediately after the blood sample was taken they underwent a tuberculin skin test (2 TU, PPD RT23, Statens Serum Institut, Copenhagen, Denmark). Those who were tuberculin test negative at recruitment (<10 mm of induration) were asked to have a repeat tuberculin test at 3 months. Tuberculin test conversion was defined as a positive...
the results and analysed them with software designed in Matlab. Brains (Isogen Biosciences), as previously described,[14] scanned by spectrophotometry. We performed Spoligotyping using mem-
previously described,[13] and assessed its concentration and purity we extracted mycobacterial DNA using CTAB and chloroform, as
individuals tested.

**SFU/well/2**

were set to at least 150 SFU/well/2

were double-entered into the same database and verified.[15] We
an Access database using visual basic code and other data were
double-entered into the same database and verified,[15] We
assessed the relationship between conversion and reversion of
tuberculin skin test results to possible risk factors using random effects logistic regression, taking into account household clustering.
We included age and gender in the final multi-variable model a priori. For skin test converters with ELISPOT results, the 4 possible combinations of positive or negative baseline and 3-month follow-up ELISPOT results were fitted using multi-nomial logistic regression. This is an extension of logistic regression that is used when there are more than two possible outcomes. After fitting the predictor effects of sleeping proximity, age and BCG scar status, the best fit was determined and the predicted probabilities for each ELISPOT combination were calculated. We then estimated the proportion of skin test converters with boosting of prior non-
tuberculous mycobacterial exposure, taking into account published estimates of the sensitivity and specificity of the ELISPOT.[12,16] Statistical analyses were conducted using Stata software (version 9; Stata Corp, College Station, TX, USA).

**RESULTS**

Between May 2002 and September 2004, 2345 contacts of 311 TB cases were recruited. Of these, 1644 (70%) were selected for an ELISPOT test in addition to a tuberculin test and had acceptable results for both (Figure 1). Of these, 799 (48.6%) were tuberculin test negative and ELISPOT negative and 174 (10.6%) were tuberculin test negative and ELISPOT positive. Table 1 shows the characteristics of these contacts and the 704 (72%) who agreed to have a repeat skin test 3 months later (table 1). Those who were tested after 3 months were slightly younger than those not tested again (mean age 17.7 years versus 22.5 years, p<0.0001) and had a slightly different ethnic mix (p = 0.038). Ninety individuals had an independent second tuberculosis reading for quality control: there was agreement with respect to a positive or negative result in 90 (98%).

One hundred and seventy six (25%) initially negative contacts had tuberculin test conversion. The proportion of contacts undergo-
ging skin test conversion increased with increasing exposure to a respective index case according to sleeping proximity (table 2, p = 0.002). It was also increased with increasing age (p = 0.0006), especially up until the age of 30 years, and in those with a visible BCG scar, although this was of borderline significance (p = 0.06). Those who were ELISPOT positive at initial screening were much more likely than those who were initially ELISPOT negative to undergo tuberculin test conversion (p = 0.0002).

One hundred and twenty-five (71%) contacts with tuberculin test conversion agreed to be re-bled for ELISPOT; 114 (91%) had an acceptable result. While 65% (n = 438 of 671; 95% confidence interval: 61.5%–68.9%) of initially tuberculin test positive contacts were ELISPOT positive, only 44% (n = 50 of 114; 95% confidence interval: 34.5%–53.5%) of tuberculin test converters were ELIS-
positive. The proportion of tuberculin test converters that were ELISPOT positive was 34.0% (18 of 53) in those with a <15 mm increase induration and 52.5% (32 of 61) of those with at least 15 mm of induration (p = 0.08). Of the 34 tuberculin test converters who were initially ELISPOT negative and had a positive repeat ELISPOT at 3 months, 32 (94%) fulfilled criteria for ELISPOT conversion. Of the 25 initially tuberculin negative, but ELISPOT positive, individuals that had tuberculin test conversion, 9 (36%) became ELISPOT negative; all 9 fulfilled criteria for ELISPOT reversion with a decrease in the combined ESAT-6/CFP-10 ELISPOT count of at least 6 spots/well.

Using multi-nomial logistic regression we modelled the probab-
ilities of the four possible combinations of recruitment and follow-
up ELISPOT results. There was a significant non-linear effect for age (p = 0.038), but sleeping proximity (p = 0.11) and BCG scar (p-value = 0.14) were not significant. Figure 2 represents the predicted probabilities for each ELISPOT combination according to age between 5 and 50 years (outside this age range the predicted probabilities had a 95% confidence interval greater than +/−0.1). Using this figure, the proportion of tuberculin test conversion due to boosting can be estimated from the predicted probability of being ELISPOT negative at both recruitment and follow-up: allowing for a specificity adjustment (assuming 80% specificity of the ELISPOT), the proportion of skin test converters estimated to have boosting ranged from 32% to 41% with increasing age.

Of the 32 community volunteers, 14 had a negative tuberculin test and ELISPOT test. All 14 had a negative ELISPOT test again.
at 1 week. At one month 9 individuals agreed to be bled again and all had a negative ELISPOT test.

One hundred and forty (79.5%) skin test converters had an x-ray performed. Of these, 4 had an x-ray that was suspicious for TB and were actively investigated. Three cases were identified (table 3). They ranged from 2 to 10 years of age; all 3 were HIV negative. With respect to the one that was culture positive, the spoligotype patterns of the index and secondary case isolates were an exact match. Both of the cases with ELISPOT results at the two time points had a rise in their ELISPOT count. One had a strongly positive ELISPOT at recruitment together with 5 mm of tuberculin test induration.

**DISCUSSION**

The interval between initial exposure and tuberculin test conversion has been shown to be a maximum of 6 weeks in 99% of individuals after BCG vaccination,[17] and 3–7 weeks following known *M. tuberculosis* exposure.[18] Furthermore, in The Gambia, TB cases that commence treatment tend not to be removed from their family compounds and remain infectious for a period of time after starting their medication. For these two reasons, a repeat screening procedure is indicated in Gambian TB case contacts that are initially negative. Here we present evidence that tuberculin skin test conversion after 3 months in such individuals is relatively increased in certain subgroups, consistent with the presence of boosting. Second, we have shown that ELISPOT is not subject to boosting by the tuberculin skin test in community volunteers. Third we demonstrate that the ELISPOT behaves in the way one would expect if it were able to distinguish those with true conversion from those with boosting.

While tuberculin test conversion in this study was associated with closer proximity to a known TB case, suggesting some genuine conversion, increased conversion with increasing age and in those with a BCG scar, provide indirect and direct evidence respectively of boosting of immunity to previous, largely non-tuberculous, mycobacterial exposure. Indeed, others have shown that individuals positive on an initial tuberculin test are much more likely to progress to TB disease than those positive only on a second test.[19,20]

We found that individuals who were tuberculin skin test negative and ELISPOT positive at screening were more likely to undergo tuberculin test conversion. Whether this reflects a shorter incubation period for the ELISPOT test, or something else, requires further study. It will also be important to determine whether ELISPOT converters are more or less likely to be initially tuberculin test positive at recruitment and if ELISPOT conversion occurs in the absence of skin test conversion. That 9 (36%) of 25 tuberculin converters who were initially ELISPOT positive had ELISPOT reversion is of concern. ELISPOT reversion is not unexpected in theory: the ELISPOT assay detects recently activated lymphocytes with immediate effector function and effector-memory cells that persist for a limited time in circulation once antigen is cleared.[21,22] If *M. tuberculosis* is either cleared
Table 1. Characteristics of TB case contacts who were negative by tuberculin test and ELISPOT at recruitment and those who had a repeat skin test at 3 months.

| Characteristic                  | Recruitment (n = 973) | 3 months (n = 704) |
|---------------------------------|-----------------------|--------------------|
| Mean (median: range) age (years)| 19.0 (15:0.5–89)      | 17.7 (13:0.5–89)   |
| 0.5–5                           | 164 (16.9%)           | 138 (19.6%)        |
| 6–15                            | 352 (36.2%)           | 275 (39.6%)        |
| 16–30                           | 299 (30.7%)           | 187 (26.6%)        |
| >30                             | 158 (16.2%)           | 104 (14.8%)        |
| Male (%)                        | 455 (46.8%)           | 324 (46.0%)        |
| Ethnic group                    |                       |                    |
| Mandinka                        | 352 (36.2%)           | 269 (38.2%)        |
| Jola                            | 242 (24.9%)           | 160 (22.7%)        |
| Wolof                           | 138 (14.2%)           | 99 (14.1%)         |
| Fula                            | 58 (6.0%)             | 47 (6.7%)          |
| Other                           | 183 (18.8%)           | 129 (18.3%)        |
| Proximity to case (%)           |                       |                    |
| Same room                       | 163 (16.8%)           | 109 (15.5%)        |
| Different room                  | 458 (47.1%)           | 338 (48.0%)        |
| Different house                 | 352 (36.2%)           | 257 (36.5%)        |
| BCG scar present               | 406 (41.7%)           | 289 (41.1%)        |
| HIV positive                    | 25 (2.6%)             | 19 (2.7%)          |

135 (13.9%) had uncertain scar status. b n = 960 tested. c n = 693 tested. doi:10.1371/journal.pone.0000183.t001

Table 2. Evaluation of possible factors associated with tuberculin test conversion at 3 months in 704 TB case contacts.

| 3 months conversion | % (n) | OR (95% CI) | p value | Adj OR (95% CI) | p value |
|---------------------|-------|-------------|---------|-----------------|---------|
| Sleep proximity     |       |             |         |                 |         |
| Different house     | 21.8  | 1.0         | 1.0     |                 |         |
| Different room      | 22.5  | 1.3 (0.8–2.1) | 1.2 (0.7–2.0) |         |         |
| Same room           | 40.4  | 3.1 (1.7–5.8) | 0.0006 | 2.9 (1.5–5.3)  | 0.002  |
| Age (years)         |       |             |         |                 |         |
| 0.5–5               | 16.7  | 1.0         | 1.0     |                 |         |
| 6–15                | 21.1  | 1.6 (0.9–2.9) | 1.3 (0.8–2.2) |         |         |
| 16–30               | 34.8  | 3.4 (1.8–6.5) | 3.2 (1.7–6.2) |         |         |
| >30                 | 28.9  | 2.4 (1.2–4.9) | 0.0005 | 1.8 (1.0–3.5)  | 0.0006 |
| Gender              |       |             |         |                 |         |
| Female              | 26.6  | 1.0         |         |                 |         |
| Male                | 23.2  | 0.8 (0.6–1.2) | 0.29   |                 |         |
| Ethnic Group        |       |             |         |                 |         |
| Mandinka            | 21.9  | 1.0         |         |                 |         |
| Jola                | 35.0  | 2.0 (1.1–3.6) |         |         |         |
| Wolof               | 20.2  | 0.7 (0.4–1.6) |         |         |         |
| Fula                | 23.4  | 1.1 (0.5–2.7) |         |         |         |
| Other               | 23.3  | 1.0 (0.5–1.9) | 0.06   |         |         |
| Recruitment ELISPOT |       |             |         |                 |         |
| negative            | 21.7  | 1.0         | 1.0     |                 |         |
| positive            | 42.5  | 3.1 (1.9–5.1) | 0.0001 | 2.7 (1.6–4.5)  | 0.0002 |
| BCG scar            |       |             |         |                 |         |
| Absent/uncertain    | 23.4  | 1.0         | 1.0     |                 |         |
| Present             | 27.3  | 1.3 (0.9–1.9) | 0.21   | 1.5 (1.0–2.3)  | 0.06   |

doi:10.1371/journal.pone.0000183.t002

Figure 2. Estimates, according to age, of the probability of TB case contacts that undergo tuberculin conversion having each of the 4 possible combinations of ELISPOT results over the 2 sampling points (recruitment and after 3 months). The estimates are derived from the study data using multi-nomial logistic regression and the analysis is restricted to those aged 5–50 years (see methods). The dotted lines represent the predicted probabilities if the sensitivity (ELISPOT +ve group) and specificity (ELISPOT −ve group) of the ELISPOT are both 80% (see methods).

doi:10.1371/journal.pone.0000183.g002

from the body or transits into dormancy, where ‘early secreted’ antigens may not be consistently secreted, one would expect ELISPOT test reversion to occur. However, it is likely that some individuals simply do not mount a strong T cell response to ESAT-6 or CFP-10 and the T cell response may vary with evolution of an
infection.[23] There is an urgent need for studies of repeated ELISPOT tests in a large number of TB case contacts. Therefore we have established a cohort of consecutively recruited TB case contacts in The Gambia that have a repeat ELISPOT test after 3 and 18 months, and a repeat skin test after 18 months.

Our ELISPOT results suggest that approximately one third of tuberculin conversion in Gambian TB case contacts is due to boosting of immunity to non-tuberculous mycobacterial exposure. It is important that a test which can identify individuals who have boosting can also identify as many as possible of those who undergo true conversion. Both secondary cases with repeat ELISPOT results were strongly ELISPOT positive at diagnosis, and the ELISPOT test probably has sensitivity of 70–85% for the diagnosis of M. tuberculosis infection from recent exposure in The Gambia,[12] and 80–90% for the diagnosis of tuberculosis disease.[16] Sensitivity to disease may vary between certain groups. For example, the commercial ‘T-spot’ ELISPOT assay detected only 9 (69%) of 13 cases with pulmonary TB but all 11 cases of extra-pulmonary TB in a recent study from Italy.[8]

The definition of tuberculin test conversion has been the subject of considerable debate. We chose a cut-off used previously in The Gambia,[15,24] in addition to a criterion of at least a 6 mm increase in induration between tests. This criterion is recommended on the basis that chance variation in the tuberculin test resulting results in less than 6 mm of induration in over 95% of individuals.[25,26] Using an alternative 10 mm increase in induration, only 3 fewer contacts would have been included as skin test converters and the findings of the study were not significantly altered (data not shown). In The Gambia we have applied mathematical tools to ELISPOT results in TB cases and their household contacts to identify a cut-off of 8 spots/well (40 spots/million cells) above the negative control well when using two antigens.[12] While we cannot be sure that we have identified exactly the right criterion for ELISPOT conversion, only 2 more individuals would have been categorised as ELISPOT converters if no criterion for an increase in spot count had been set, other than for the test to turn positive; and only 2 individuals would have been re-categorised as non-converters if a 10 spot increase had been specified.

At the present time, treatment of M. tuberculosis infection is prohibitively expensive and impractical in many developing countries. In the United States, it is advised that those case contacts who are initially screened during the ‘window period’, and have a negative result, should have a repeat tuberculin test - all those that become tuberculin positive are offered prophylactic treatment.[27] Any possible way to help distinguish TB case contacts that would benefit from prophylactic treatment and those that wouldn’t is therefore of relevance in both developing and developed country settings. Further longitudinal studies are indicated to help confirm that our findings are of practical importance in this regard, and to address the relevance of ELISPOT reversion in particular. It does appear that an ELISPOT assay may have a niche in exposing boosting of immunity to non-tuberculous mycobacterial exposure.

ACKNOWLEDGMENTS

We thank our field workers and laboratory assistants for their hard work. Professors Adrian Hill and Sarah Rowland-Jones gave helpful advice with respect to defining ELISPOT conversion.

Author Contributions

Conceived and designed the experiments: RB DJ AF RA KM TC DJ. Performed the experiments: RB AF ML RA DJ Bd. Analyzed the data: DJ PH AF ML SD. Wrote the paper: DJ PH.

REFERENCES

1. Guwatudde D, Nakakato M, Jones-Lopez EC, Maganda A, Chiuma A, et al. (2003) Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol 158: 887–898.
2. Tukey JW, DuFour EH, Scibert F (1950) Lack of sensitivity following repeated skin tests with standard tuberculin (PPD-S). Am Rev Tuberc 62: 7–86.
3. National Institute for Health and Clinical Excellence (2006) Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence. Clinical Guideline: 33: 1–66.
4. Levy MZ, Medeiros EA, Shang N, Soares MC, Honarko AS, et al. (2003) TST reversion in a BCG-revaccinated population of nursing and medical students, Sao Paulo, Brazil, 1997–2000. Int J Tuberc Lung Dis 9: 771–776.
5. Palmer CE (1952) BCG vaccination and tuberculosis allergy. Lancet 1: 935–940.
6. Ever K, Deeks J, Alvarez I, Bryant G, Waller S, et al. (2003) Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361: 1168–1173.
7. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, et al. (2004) Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infec Dis 38: 966–973.
8. Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, et al. (2006) Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367: 1328–1334.
9. Adegbola RA, Hill P, Baldeh I, Oro J, Sarz R, et al. (2003) Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia. Int J Tuberc Lung Dis 7: 390–393.
10. Schim van der Loef MF, Sarpe-Njie R, Ceesay S, Awazuza AA, Jaye P, et al. (2003) Regional differences in HIV trends in The Gambia: results from sentinel surveillance among pregnant women. AIDS 17: 1841–1846.
11. Lahani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, et al. (2001) Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163: 824–829.
12. Jeffries DJ, Hill PC, Fox A, Augus M, Jackson-Sillah DJ, et al. (2006) Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. Int J Tuberc Lung Dis 10: 192–198.
13. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, et al. (1993) Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 31: 406–409.

14. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, et al. (1997) Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907–914.

15. Jeffries DJ, Doukor S, Brookes RH, Fox A, Hill PC (2004) Design and implementation of relational databases relevant to the diverse needs of a tuberculosis case contact study in the Gambia. Int J Tuberc Lung Dis 8: 1095–1099.

16. Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah DJ, et al. (2006) Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 6: 66.

17. Edwards LB, Palmer CE, Magnus K (1953) Response to BCG vaccination. BCG vaccination studies by the WHO research office. Geneva: World Health Organisation.

18. Wasz-Hockert O (1947) On the period of incubation in tuberculosis. Ann Med Fenn 96: 764–772.

19. Anonymous (1956) BCG and yole bacillus vaccines in the prevention of tuberculosis in adolescents. First (progress) report to the Medical Research Council by their tuberculosis vaccines clinical trials committee. BMJ 1: 413–427.

20. Comstock GW, Webster RG (1969) Tuberculosis studies in Muscogee county, Georgia: VII. a twenty-year evaluation of BCG vaccination in a school population. Am Rev Respir Dis 100: 839–845.

21. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, et al. (2001) Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4+ T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 167: 5217–5223.

22. Godkin AJ, Thomas HC, Openshaw PJ (2002) Evolution of epitope-specific memory CD4+ T cells after clearance of hepatitis C virus. J Immunol 169: 2210–2214.

23. Vekemans J, Lienhardt C, Sillah JS, Wheeler JG, Lahai GP, et al. (2001) Tuberculous contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect Immun 69: 6554–6557.

24. Lienhardt C, Fielding K, Sillah J, Tunkara A, Doukor S, et al. (2003) Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med 168: 448–455.

25. Menzies R (1999) Interpretation of repeated tuberculin tests. Am J Respir Crit Care Med 159: 15–21.

26. Pouchot J, Grosland A, Collet C, Coste J, Eudaile JM, et al. (1997) Reliability of tuberculin skin test measurement. Ann Intern Med 126: 210–214.

27. CDC (2005) Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54: 1–47.
